Companies
Positive results from a randomized study in healthy volunteers mark a key milestone for Alvotech’s proposed Entyvio rivals AVT80 and AVT16.
Slovenia’s Krka is ramping up capital spending to expand global manufacturing capacity, betting that industrial scale and supply resilience will drive its next phase of growth.
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
Teva is lining up Europe as the next regulatory market for its long-acting injectable olanzapine, following its US filing late last year, as the company looks to build a global schizophrenia franchise.
Teva says it has 10 additional biosimilars in development for launch from 2028 onwards, extending its portfolio beyond 2027 as it targets European growth and expands through partnerships.
ANI’s Cortrophin Gel is benefiting from significant under-penetration in areas such as nephrology, neurology, rheumatology and pulmonology, the firm told attendees to the recent J.P. Morgan Healthcare Conference.
Amid Pfizer’s acquisition of Metsera and Hanmi’s novel contender moving to the approval stage, South Korean obesity assets are poised to attract more interest from global pharma firms and investors.
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
After years of restructuring and remediation, Viatris says its base business has stabilized and it now expects cost savings, new launches and business development to drive renewed growth beginning in 2026.
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
Latest agreement with Rosemont underscores Hyloris’ value-added medicines strategy and asset-light US partnering.
Alvotech has unveiled a planned leadership transition, with founder and chairman Róbert Wessman handing the chief executive role to long-time collaborator Lisa Graver as the biosimilars specialist prepares for its next phase of growth.